- Price
- $1.98
- Day
- +5.04%
- Mkt Cap
- $356.57M
- 52W Range
- $1.61 – $6.88
- Volume
- 3.04M
- Beta
- 0.75
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its abstract titled “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer” has been accepted for an oral Proffered Paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. The congress will take place October 23-27, 2026 in Madrid, Spain.
Read full article
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. CMPX's lead asset, tovecimig, showed strong PFS benefit in BTC, but OS crossover contamination clouds FDA approval prospects. The Q3 2026 FDA meeting is pivotal; approval could nearly double the stock, while rejection risks 50% dilution and multi-year delays.
Read full article